By addressing translational challenges and tackling off-target toxicities, the 2nd ADC Toxicity Summit is returning at an imperative time to allow you to prevent, predict and mitigate toxicities ...

Led by a team of distinguished toxicology experts, TriApex was thrilled to take part in this prestigious meeting, engaging in ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for undisclosed cancer targets.

"P-Sam is an exciting new ADC targeting B7-H4 ... unacceptable drug-related toxicity, or withdrawal of consent. Almost all patients in the study (94%) had received prior platinum chemotherapy ...

Elevation Oncology to discontinue development of EO-3021, a Claudin 18.2 ADC to treat advanced unresectable or metastatic gastric and GEJ: Boston Saturday, March 22, 2025, 15:00 H ...

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 ...

Elevation Oncology (ELEV) announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug ...